Sort
8,912 grants matching “sars cov 2”
STTR Phase I: Discovery and Development of Macrocyclic Peptide Inhibitors of SARS-COV-2 Spike Protein for the Treatment of COVID-19
$255,473Shoutian Zhu · Phenotarget Biosciences, Inc. · · FY2021 · TIP
SBIR Phase I: Rapid Antigen-based SERS assay for COVID-19 Detection (COVID-19)
$255,468Joel S Tabb · Ionica Sciences · · FY2020 · TIP
Deciphering the Molecular Mechanisms of Response to COVID Vaccine in Kidney Transplant Recipients
$255,459Jonathan S Maltzman · Palo Alto Veterans Instit For Research · R21 · FY2023 · AI
Core C - Proteomics Core
$255,298George Georgiou Georgiou · Washington University · U19 · FY2025 · AI
The COVID-19 vaccine efficacy among people living with and without HIV: a real-world data approach
$255,091Xueying Yang · University Of South Carolina At Columbia · R21 · FY2022 · AI
Core B Clinical Core
$255,048Tara F Carr · University Of Arizona · U19 · FY2023 · AI
CORALE-SeroNet Immune Bioanalytics Core
$255,024Jennifer E Van Eyk · Cedars-Sinai Medical Center · U54 · FY2022 · CA
T cell modulation of COVID-19 disease
$255,000Nicholas James Maness · Tulane University Of Louisiana · R21 · FY2021 · AI
A randomized crossover trial of portable air cleaners to reduce PM and SARS-CoV-2 exposures at home
$254,770Helmut Zarbl · Rbhs-School Of Public Health · P30 · FY2020 · ES
Per- and Polyfluoroalkyl substances (PFAS) Exposures and COVID-19 in Firefighters
$254,748Jefferey L Burgess · University Of Arizona · R21 · FY2020 · ES
Development of SARS-CoV-2 nanoparticles through a plug-and-play approach
$254,737Baoshan Zhang · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Immunogen Design for SARS-CoV-2
$254,737Peter D Kwong · National Institute Of Allergy And Infectious Diseases · ZIA · FY2020 · AI
Viral exposure signatures may define individuals vulnerable for COVID-19
$254,693Xin Wei Wang · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Control of coronavirus pathogenesis by antagonism of RNase L
$254,625Susan R. Weiss · University Of Pennsylvania · R21 · FY2015 · AI
Discovery of GPCR-active natural products and their biosynthetic genes from the human associated bacteria
$254,250Sean F Brady · Rockefeller University · R01 · FY2020 · AT
Single gene inborn errors of immunity underlying SARS-CoV-2-related multisystem inflammatory syndrome in children: a new approach to tackle a seemingly old puzzle
$254,250Shen-Ying Zhang · Rockefeller University · R21 · FY2022 · AI
Functional characterization of SARS-CoV-2 myeloid cell receptors as an immunopathogenic mechanisms of COVID-19
$254,250Jun Wang · New York University School Of Medicine · R21 · FY2021 · AI
A SARS-CoV-2 Breathalyzer for Direct Virus Detection
$254,027Patricia Bea Keady · Aerosol Devices, Inc. · R42 · FY2021 · DE
Admin Core
$253,936Scott Dexter Boyd · Stanford University · U54 · FY2022 · CA
SBIR Phase I: COVID-19: Robots for Automating Indoor Disinfection Tasks with Existing Non-Autonomous Devices
$253,836Bradley Oosterveld · Thinking Robots Inc. · · FY2021 · TIP
Multi-dimensional comparison of differentially pathogenic coronaviruses (CoV) in human lung tissue
$253,750Jean Kyou Lim · Icahn School Of Medicine At Mount Sinai · R21 · FY2021 · AI
Project 1
$253,705Abraam M. Yakoub · University Of North Dakota · P20 · FY2021 · GM
Critical neutralizing domain-based vaccines against new SARS-like virus hCoV-EMC
$253,650Lanying Du · New York Blood Center · R21 · FY2015 · AI
Administrative Core
$253,527Viviana A Simon · Icahn School Of Medicine At Mount Sinai · P01 · FY2023 · AI
Leveraging Pathogen-Host Networks to Identify Virus-specific and Estradiol-regulated Mechanisms during Respiratory Infection
$253,510Jason Edward Shoemaker · University Of Pittsburgh At Pittsburgh · R21 · FY2023 · AI